Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Currently, there are no approved treatments by the US Food and Drug Administration or
European Medicines Agency available for prevention or treatment of chemotherapy induced PN.
There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral
neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by
paclitaxel. These cells are myelin-forming peripheral glial cells which maintain nerve
function. The intracellular cyclic adenosine monophosphate has a critical role in Schwann
cell differentiation, there is a hypothesis that phosphodiesterase inhibitors, which increase
the intracellular cAMP level, could prevent paclitaxel-induced dedifferentiation of Schwann
cells. At the preclinical level, cilostazol potently inhibited paclitaxel-induced
dedifferentiation of cultured Schwann cells, yet this positive effect have not been
clinically investigated. Therefore, the aim of this study is to evaluate the effect of
cilostazol on the amelioration of paclitaxel induced PN in breast cancer patients.